Hepatitis B and d Protocols: Immunology Model Systems, and Clinical Studies. Questo articolo non è disponibile.Hepatitis B and d Protocols: Immunology Model Systems, and Clinical Studies

Despite the availability of an effective vaccine, there are still 400 million people, worldwide who are chronically infected with hepatitis B virus (HBV). For them, the vaccine, as currently applied, has no value. Given the possible consequences of HBV infection, the number of those chronically infected with HBV presents an enormous public health challenge. For example, the major etiology of hepatocellular carcinoma (HCC) is chronic infection with HBV. Although fifth in cancer incidence, worldwide, HCC/liver cancer is the third leading cause of cancer death. The high mortality as- ciated with HCC arises because the disease is often detected late and is unresponsive to treatment. The number of deaths caused by PHCC is expected to rise over the next 20 years. Those chronically infected with HBV have a life risk of death to HCC of between 10 and 25%. Even the limited efficacy of drugs for the treatment of chronic HBV helps underscore the point that this disease is responsive to therapy. Drugs that target the polymerase (e. g. , hepsera and lamivudine) and interferon alpha represent two distinct strategies and show that both conventional antiviral and immunothe- peutic approaches can be used in management. However, the current inventory of therapeutics is inadequate. Interferon alpha is of limited value, only parenterally ava- able, and fraught with adverse reactions.

Despite the availability of an effective vaccine, there are still 400 million people worldwide who are chronically infected with the hepatitis B and D viruses (HBV and HDV), and more work still needs to be done in all of the key areas of managing the disease. In Hepatitis B and D Protocols, leading investigators and clinicians have joined forces to create a broad-ranging collection of cutting-edge techniques for the study of HBV and HDV infections and for the development of therapies to treat them. In this second of two volumes, Immunology, Model Systems, and Clinical Studies, the authors focus on protocols for the study of host immune responses to infection, in vitro and in vivo models of infection, and the development of antivirals. Each fully tested protocol is described in step-by-step detail by an established expert in the field and includes a background introduction outlining the principle underlying the technique, equipment and reagent lists, and tips on troubleshooting and avoiding known pitfalls. An accompanying first volume, Detection, Genotypes, and Characterization, contains user-friendly protocols for the identification and quantification of viral markers, the detection and impact of viral variants, and the study of the viral life cycle.
Taken together, Hepatitis B and D Protocols, Volume 1: Detection, Genotypes, and Characterization and Volume 2: Immunology, Model Systems, and Clinical Studies offer both new and experienced investigators an encyclopedic collection of powerful tools for studying HBV and HDV infections, as well as an essential resource for finding new therapies to treat chronically infected patients.